Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Do Not Coadminister

Tenofovir-DF (TDF)

Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)

Quality of Evidence: Very Low

Summary:

Emtricitabine/tenofovir-DF should not be administered with additional tenofovir-DF. Coadministration of tenofovir-DF (300 mg once daily) and emtricitabine (200 mg once daily for 7 days) had no effect on tenofovir AUC, Cmax or Cmin; emtricitabine AUC and Cmax were unaltered and there was a 20% increase in Cmin (n=17).

Description:

Emtricitabine/tenofovir-DF should not be administered concomitantly with other medicinal products containing tenofovir disoproxil.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.

No clinically significant drug interactions have been observed between FTC and tenofovir. Coadministration of tenofovir-DF (300 mg once daily) and emtricitabine (200 mg once daily) was studied in 17 subjects. There was no change in FTC Cmax or AUC, but Cmin increased by 20%. Tenofovir Cmax, AUC and Cmin were unaltered.
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.

View all available interactions with Tenofovir-DF (TDF) by clicking here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2025 The University of Liverpool. All rights reserved.